• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DANAZOL Drug Record

  • Summary
  • Interactions
  • Claims
  • DANAZOL chembl:CHEMBL1479 ApprovedAntineoplastic

    Alternate Names:

    DANOCRINE
    DANAZOL
    NSC-270916
    WIN-17757
    DANAZOLUM
    CYCLOMEN
    DANOCRINE®
    drugbank:01406
    rxcui:3102
    chembl:CHEMBL1479
    pubchem.compound:28417
    chemidplus:17230-88-5

    Drug Info:

    FDA Approval 1976
    Drug Class small molecule
    Drug Indications Antiendometriosis Agent, Antineoplastic Agent
    Drug Class antiendometriosis agent
    Year of Approval 1976
    Drug Class antineoplastic agent
    (4 More Sources)

    Publications:

    Gomez et al., 2000, Effects of androgen treatment on expression of macrophage Fcgamma receptors., Clin. Diagn. Lab. Immunol.
    Roselli, 1998, The effect of anabolic-androgenic steroids on aromatase activity and androgen receptor binding in the rat preoptic area., Brain Res.
    Donaldson, 1989, Danazol., Am. J. Med.
    Sasagawa et al., 2008, Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile., Steroids
    Dmowski, 1990, Danazol. A synthetic steroid with diverse biologic effects., J Reprod Med
    Shepherd, 1995, Danazol and plasma lipoprotein metabolism., Int J Gynaecol Obstet
    Bower et al., Failure of the synthetic androgen, danazol, to increase protein S levels and prevent thrombosis in a patient with severe protein S deficiency., Haemostasis
    Cugno et al., 1988, Haemostasis contact system and fibrinolysis in hereditary angioedema (C1-inhibitor deficiency)., J. Clin. Chem. Clin. Biochem.
    Beaumont et al., 2002, Danazol for heavy menstrual bleeding., Cochrane Database Syst Rev
    Sanfilippo et al., 1985, Evaluation of danazol influence upon the uterus using scanning electron microscopic morphometric and biochemical analyses., Surg Gynecol Obstet
    Snyder et al., 1990, Danazol suppression of luteinizing hormone in the rat: evidence for mediation by both androgen and estrogen receptors., Proc. Soc. Exp. Biol. Med.
    Fujimoto et al., 1995, Danazol decreases transcription of estrogen receptor gene in human monocytes., Gen. Pharmacol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Menon et al., 1986, Inhibition of gonadotropin-releasing hormone receptors in rat anterior pituitary monolayer cell cultures by danazol., Am. J. Obstet. Gynecol.
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Tang et al., 2005, [Effects of xianggui pill on cytokine in endometriosis model rat]., Zhongguo Zhong Yao Za Zhi
    Lee CA et al., 2010, Identification of novel substrates for human cytochrome P450 2J2., Drug Metab Dispos
    Tian et al., 2003, [Effect of Chinese herbal medicine for nourishing yin and purging fire on mRNA expressions of gonadotropin-releasing hormone and its receptor in precocious puberty model rats]., Zhongguo Zhong Xi Yi Jie He Za Zhi
    Roth et al., 2004, Pituitary and gonadal effects of GnRH (gonadotropin releasing hormone) analogues in two peripubertal female rat models., Pediatr. Res.
    Laurell et al., 1979, A comparison of plasma protein changes induced by danazol, pregnancy, and estrogens., J. Clin. Endocrinol. Metab.
    Huang et al., 1994, [Effects of gossypol acetate, danazol, progesterone and GnRH-A on estrogen and progesterone receptors of human endometrial cells]., Zhongguo Zhong Xi Yi Jie He Za Zhi
    Beaumont et al., 2007, Danazol for heavy menstrual bleeding., Cochrane Database Syst Rev
    Prost-Avallet et al., 1991, In vitro effect of synthetic progestogens on estrone sulfatase activity in human breast carcinoma., J. Steroid Biochem. Mol. Biol.
    Menon et al., 1980, Evidence that danazol inhibits gonadotropin-induced ovarian steroidogenesis at a point distal to gonadotropin-receptor interaction and adenosine 3',5' cyclic monophosphate formation., Am. J. Obstet. Gynecol.
  • DANAZOL   MBL2

    Interaction Score: 7.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12076401


    Sources:
    NCI

  • DANAZOL   GNRHR2

    Interaction Score: 2.9

    Interaction Types & Directionality:
    negative modulator (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    3004220 17016423 17139284 2404115


    Sources:
    TdgClinicalTrial TEND

  • DANAZOL   CGB5

    Interaction Score: 2.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    6243863


    Sources:
    NCI

  • DANAZOL   STS

    Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1751397


    Sources:
    NCI

  • DANAZOL   GNRHR

    Interaction Score: 0.77

    Interaction Types & Directionality:
    negative modulator (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    14571621 3004220 14605254 2404115


    Sources:
    TdgClinicalTrial TEND

  • DANAZOL   CYP2J2

    Interaction Score: 0.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19923256


    Sources:
    PharmGKB

  • DANAZOL   CP

    Interaction Score: 0.55

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    489712


    Sources:
    NCI

  • DANAZOL   PLG

    Interaction Score: 0.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8529771 7607583 3146615


    Sources:
    NCI

  • DANAZOL   PGR

    Interaction Score: 0.38

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Progesterone receptor agonist
    Direct Interaction yes

    PMIDs:
    8000225 17636649 18061638 2404115


    Sources:
    ChemblInteractions

  • DANAZOL   ESR1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    4039467 2326286 7540578 11752352


    Sources:
    DTC TdgClinicalTrial TEND TTD

  • DANAZOL   CXCL8

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16161451


    Sources:
    NCI

  • DANAZOL   AR

    Interaction Score: 0.03

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Androgen Receptor agonist

    PMIDs:
    10882672 9593936 2486535 18061638 2404115


    Sources:
    DTC ChemblInteractions

  • DANAZOL   CYP2C9

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • DANAZOL   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • DANAZOL   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • DANAZOL   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TEND: DANAZOL

    • Version: 01-August-2011

    Alternate Names:
    DANAZOL Primary Drug Name

    Drug Info:
    Drug Class antineoplastic agent
    Year of Approval 1976
    Drug Class antiendometriosis agent

    Publications:

  • TdgClinicalTrial: DANAZOL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antiendometriosis Agent, Antineoplastic Agent
    Drug Class small molecule
    FDA Approval 1976

    Publications:

  • NCI: DANAZOL

    • Version: 14-September-2017

    Alternate Names:
    C414 NCI drug code

    Drug Info:

    Publications:
    Tang et al., 2005, [Effects of xianggui pill on cytokine in endometriosis model rat]., Zhongguo Zhong Yao Za Zhi
    Menon et al., 1980, Evidence that danazol inhibits gonadotropin-induced ovarian steroidogenesis at a point distal to gonadotropin-receptor interaction and adenosine 3',5' cyclic monophosphate formation., Am. J. Obstet. Gynecol.
    Shepherd, 1995, Danazol and plasma lipoprotein metabolism., Int J Gynaecol Obstet

  • DTC: DANAZOL

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1479 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: danazol

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Lee CA et al., 2010, Identification of novel substrates for human cytochrome P450 2J2., Drug Metab Dispos

  • TTD: Danazol

    • Version: 2020.06.01

    Alternate Names:
    D09IPV TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1479

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1479

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21